MC2 Therapeutics A/S: Financial statements 2022
CVR: 29526346
Source: annual report 2022, Danish Business Authority
01/01/2022 – 31/12/2022
MC2 Therapeutics A/S (CVR 29526346) has filed annual accounts for 2022. In 2022, the company reported a gross profit of DKK 25,008,167 and a net result of DKK -101,331,259 compared with DKK -25,222,958 the year before. That is a decrease of 9.8% compared with the year before. Equity in the 2022 report amounted to DKK -122,649,951. The company had 30 employees in the financial year.
- Gross Profit
- DKK 25,008,167
- Profit/Loss
- DKK -101,331,259
- Equity
- DKK -122,649,951
- Total Assets
- DKK 38,592,343
- Employees
- 30
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2022 | - | 25M | -101.3M | -122.6M | 30 |
| 2021 | - | 27.7M | -25.2M | -21.1M | 19 |
| 2020 | - | 15.9M | -86.9M | 13.9M | - |
| 2019 | - | 13.7M | -81.4M | 65.8M | 11 |
| 2018 | - | 13.3M | -110.1M | 62.3M | 10 |
Official annual report
Keep an eye on MC2 Therapeutics A/S
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2022
As of November 8, 2022, Mette Vagner Johannesen has left the board of directors of MC2 Therapeutics A/S.
MC2 Therapeutics A/S has published its annual report for 2021. Gross profit came to DKK 27,734,440, and the net result was DKK -25,222,958.
About MC2 Therapeutics A/S
MC2 Therapeutics A/S is a Danish company of the type Aktieselskab based in Hørsholm, founded in 2006. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named MC2 Therapeutics ApS and MC2 BIOTEK ApS. The management consists of Trine Ahlgreen. The board consists of Mads Jørgen Nøhr Clausen (chair), Anders Dahlgaard Hove, John Sørensen Haurum and Tomas Dahl Mikkelsen. The company is owned by Alsmark Invest II ApS, MC2 HOLDING ApS and Selskabet af 4. april 2023 ApS. The company has 8 employees (2026). In 2025, the company reported a gross profit of DKK 22,248,504 and a net result of DKK -7,816,954 compared with DKK -53,006,931 the year before. Equity in the 2025 report amounted to DKK -224,478,927.